Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19
Status:
Terminated
Trial end date:
2020-08-07
Target enrollment:
Participant gender:
Summary
Single blind randomized clinical trial designed to evaluate the efficacy of the combination
of hydroxychloroquine and dexamethasone as treatment for severe Acute Respiratory Distress
Syndrome (ARDS) related to coronavirus disease 19 (COVID-19). We hypothesize that
dexamethasone (20 mg for 5 days followed by 10 mg for 5 days) combined with 600 mg per day
dose of hydroxychloroquine for 10 days will reduce the 28-day mortality compared to
hydroxychloroquine alone in patients with severe ARDS related COVID-19.